Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEARTS
- Development stage
- Preclinical
- Lead developer
- ARTBIO
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HEARTS is a discovery-stage alpha radioligand therapy (ART) program developed by ARTBIO, specifically designed to address multiple targets across a variety of solid tumors. Utilizing Lead-212 (212Pb) as its radioactive payload, HEARTS delivers high-linear energy transfer (LET) alpha particles directly to tumor cells. These alpha particles induce lethal double-strand DNA breaks, which are difficult for cells to repair, potentially overcoming resistance to standard treatments. The program is supported by ARTBIO's AlphaDirect technology, which ensures a reliable supply of high-purity 212Pb, and a proprietary platform for optimizing the delivery of the isotope to diverse cancer targets.
02
Targets
DNA
Beyond the preview
Go deeper on HEARTS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEARTS.